A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates.
Cell Rep Med
; 2(11): 100448, 2021 11 16.
Article
em En
| MEDLINE
| ID: mdl-34723223
ABSTRACT
Activation of nucleic acid sensing Toll-like receptors (TLRs) in B cells is involved in antiviral responses by promoting B cell activation and germinal center responses. In order to take advantage of this natural pathway for vaccine development, synthetic pathogen-like antigens (PLAs) constructed of multivalent antigens with encapsulated TLR ligands can be used to activate B cell antigen receptors and TLRs in a synergistic manner. Here we report a PLA-based coronavirus disease 2019 (COVID-19) vaccine candidate designed by combining a phage-derived virus-like particle carrying bacterial RNA as TLR ligands with the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein as the target antigen. This PLA-based vaccine candidate induces robust neutralizing antibodies in both mice and non-human primates (NHPs). Using a NHP infection model, we demonstrate that the viral clearance is accelerated in vaccinated animals. In addition, the PLA-based vaccine induces a T helper 1 (Th1)-oriented response and a durable memory, supporting its potential for further clinical development.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos B
/
Anticorpos Neutralizantes
/
Glicoproteína da Espícula de Coronavírus
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
Anticorpos Antivirais
Limite:
Animals
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article